Clinical Trials
14 trialsNCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT03704688 2025-05-16
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03690115 2025-03-25
PONALLO
Versailles Hospital
Phase 2 Completed
NCT02272998 2025-03-24
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT01935336 2022-02-11
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
Phase 2 Completed
NCT01641107 2021-11-30
LAL1811
Incyte Corporation
Phase 2 Completed
NCT01207440 2021-02-02
PACE
Takeda
Phase 2 Completed
NCT02265341 2020-11-25
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Mayo Clinic
Phase 2 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01813734 2019-12-24
Ponatinib in Advanced NSCLC w/ RET Translocations
Massachusetts General Hospital
Phase 2 Completed
NCT02478164 2018-07-24
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed
NCT00660920 2018-05-16
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Takeda
Phase 1 Completed